Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-064094
Filing Date
2024-08-01
Accepted
2024-08-01 16:15:13
Documents
17
Period of Report
2024-04-01
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0210045-8ka1_aditxt.htm   iXBRL 8-K/A 35168
2 AUDITED FINANCIAL STATEMENTS OF APPILI THERAPEUTICS, INC. AS OF MARCH 31, 2024 A ea021004501ex99-1_aditxt.htm EX-99.1 432810
3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION AS OF AND FOR THE THREE MONTH ea021004501ex99-2_aditxt.htm EX-99.2 472209
4 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 ea021004501ex99-3_aditxt.htm EX-99.3 268119
5 GRAPHIC ex99-1_001.jpg GRAPHIC 2038
  Complete submission text file 0001213900-24-064094.txt   1503664

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE adtx-20240401.xsd EX-101.SCH 3009
7 XBRL LABEL FILE adtx-20240401_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE adtx-20240401_pre.xml EX-101.PRE 22355
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0210045-8ka1_aditxt_htm.xml XML 7278
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39336 | Film No.: 241166881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)